Primary aldosteronism, a common entity? the myth persists

Area of Science:

• Endocrinology
• Hypertension Research
• Clinical Biochemistry

Background:

• Primary hyperaldosteronism is a significant cause of hypertension.
• It is characterized by excess aldosterone production and suppressed plasma renin levels.
• Surgical cure is possible for aldosterone-secreting adenomas, but not for nodular hyperplasia.

Purpose of the Study:

• To critically examine the diagnostic utility of the aldosterone-to-renin ratio (ARR) in primary hyperaldosteronism.
• To evaluate whether an abnormal ARR reliably identifies mineralocorticoid hypertension.
• To assess the clinical implications of widespread ARR screening.

Main Methods:

• Literature review and critical analysis of existing studies on primary hyperaldosteronism and ARR testing.
• Examination of the biochemical definition of hyperaldosteronism and its relationship with renin levels.
• Assessment of the prevalence and clinical characteristics of patients identified by ARR screening.

Main Results:

• An abnormal ARR is often a marker of the low-renin state rather than definitive mineralocorticoid hypertension.
• Many patients identified by ARR screening have low-renin hypertension, which is not amenable to specific therapies.
• True primary hyperaldosteronism (Conn's syndrome) is less common than suggested by ARR screening.

Conclusions:

• The aldosterone-to-renin ratio test may not be a sufficiently specific or cost-effective screening tool for primary hyperaldosteronism.
• Widespread use of ARR testing may lead to overdiagnosis of mineralocorticoid hypertension and unnecessary investigations.
• Further controlled trials are needed to validate claims regarding spironolactone sensitivity in patients with abnormal ARR results.